Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Biogen Inc.
(Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.
'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.'
Key Scientific Sessions and Presentations:
Educational Program on Tau in Alzheimer's Disease
At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on
KnowTau.com
, building on the resources already available.
For more information, please see the AAIC 2025
program
and visit the Biogen AAIC booth.
About BIIB080
BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease.
In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis.
About LEQEMBI ® (lecanemab)
LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023.
LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Please see full U.S.
Prescribing Information
for LEQEMBI, including Boxed WARNING and
Medication Guide
.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at
www.biogen.com
. Follow us on social media -
,
,
X
,
YouTube
.
Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
27 minutes ago
- Bloomberg
Lilly Gets Limited European Backing for Alzheimer's Disease Drug
Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer's disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second drug in the region to slow the most common cause of dementia in the elderly. The European Medicines Agency 's drug advisory panel recommended granting a marketing authorization for Kisunla in patients who don't carry a specific gene that can increase the risk of a potentially fatal brain-swelling condition called ARIA. In the US, the medicine is approved for a much wider group of patients. The EU previously approved a similar medicine from Eisai Co. and Biogen Inc called Leqembi though its use was also limited to patients at lower risk for brain swelling.
Hamilton Spectator
41 minutes ago
- Hamilton Spectator
Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of Science and Health
A Thousand Cuts, Sujata Setia, 2023, Urban Travel, Mithail Afrige Chowdhury, 2023, Cholesterol in the Liver, 2022, Steve Gschmeissner Click Here to download press images and captions LONDON, July 25, 2025 (GLOBE NEWSWIRE) — Wellcome's 2025 Photography Prize celebrates three image makers whose work reveals the human stories behind science and health. UK-based artist Sujata Setia, Bangladeshi documentary and street photographer Mithail Afrige Chowdhury, and UK-based electron microscopy specialist and science photographer Steve Gschmeissner have each been awarded a £10,000 prize for powerful images that reflect how science and health shape people's lives in complex and deeply personal ways, from the from the hidden toll of domestic abuse to the everyday realities of climate migration, to the microscopic processes that underpin heart disease. Now in its 28th year, the Wellcome Photography Prize celebrates compelling imagery at the intersection of science, health and human experience. From documentary photography to microscopy and medical imaging, it highlights diverse perspectives on global health and the vital role of visual storytelling in creating a healthier future. The top 25 entries are now on display in the Wellcome Photography Prize 2025 exhibition, which is free and open to the public at the Francis Crick Institute in London, running until 18 October 2025. Each of the finalists has received a £1,000 prize, with a total of £52,000 awarded across the competition. Lara Clements, Associate Director, Engagement, Wellcome, says, ' The Wellcome Photography Prize offers image-makers a platform to showcase the impact of science and health on lives around the world. This year's winning works stood out not only for their technical accomplishment, but for the care and collaboration behind them. Sujata Setia's portraits raised powerful questions around dignity, confidentiality and sensitivity. Mithail Afrige Chowdhury's image exemplified the value of being embedded in the community and explored themes of adaptation, illusion and fantasy in a compelling way. Steve Gschmeissner's biomedical image impressed us with its precision and raised important questions about how scientific imagery is shared and understood by the public. We hope audiences will find the winners' work moving, educational and inspiring, and enjoy the full exhibition at the Francis Crick Institute.' The Winners In the Storytelling Series category, Sujata Setia was recognised for A Thousand Cuts , a deeply collaborative portrait project developed with survivors of domestic abuse within South Asian communities. Each image is a composite of personal testimony, visual symbolism, and traditional craft. Setia worked with the women and with the charity SHEWISE to create portraits that protected anonymity without erasing identity, applying the Indian paper-cutting technique sanjhi to overlay each photograph. The results are intimate, powerful reflections on generational trauma, silence, survival, and the politics of representation. From the account of a woman forced into marriage twice by her father and left with lasting PTSD, to a mother determined to break the cycle of violence for her daughter, the series captures how abuse can become ingrained and normalised, and how art can offer a means of reclaiming narrative. Sujata Setia says, ' This is a monumental recognition. A Thousand Cuts being selected for Wellcome Photography Prize affirms that health cannot be separated from the histories that shape it. And that domestic abuse is never a singular event; it leaves a direct, trans-generational imprint on health. As a child who grew up in a home where violence was a daily occurrence, I carry that trauma like another limb. This recognition validates not just my story, but the invisible, intangible, yet deeply scarring legacy of gender-based abuse. Domestic abuse is one of the most widespread global crimes; and yet remains among the least publicly acknowledged health crises. I hope this moment becomes a catalyst for deeper dialogue and scholarship around the interrelation between domestic abuse and health. That is our collective hope.' Mithail Afrige Chowdhury was awarded the Striking Solo Photography prize for Urban Travel , a deceptively gentle image of a mother and daughter on a rooftop picnic in Dhaka. With few parks left in the city due to rapid urbanisation, this staged moment, a simple attempt to give a child a taste of nature, becomes an act of resilience. Nearly half of Dhaka's population today are climate migrants, displaced by increasingly extreme weather, and Chowdhury's work highlights the everyday consequences of these shifts: the loss of green space, of childhood rituals, of breath. The photograph is tender, composed, and yet filled with tension, a portrait of care and adaptation under invisible pressures. Mithail Afrige Chowdhury says, ' When I got the news, the first thing I did was charge my camera—not to take a photo, but to restart something I thought I'd lost. I won't dwell on personal or professional hardships, but this moment means more than I can say. I made this image two years ago, as part of a major project on climate change, urban sustainability, and public health. Then life intervened, and fear slowly pulled me away from the work I loved. But now, I can wake up with an objective. Because someone has my back. And that makes all the difference. Awards can feel technical but this recognition from Wellcome feels deeply human.' The winner of The Marvels of Scientific and Medical Imaging was announced as Steve Gschmeissner, whose electron microscopy image Cholesterol in the Liver reveals cholesterol crystals (shown in blue) forming inside lipid-laden liver cells (purple). These microscopic shifts, invisible to the naked eye, can have deadly consequences: when cholesterol hardens from liquid to crystal, it damages blood vessels and contributes to heart disease and strokes. Gschmeissner's colourised SEM image transforms this biological process into something visually striking, part data, part artwork. With a career spanning over four decades, and more than 10,000 images published in scientific journals, stamp collections, fashion collaborations, and music albums, his work exemplifies how imaging can bridge science and culture. Steve Gschmeissner says, ' When I discovered that Wellcome had reintroduced the Marvels of Scientific and Medical Imaging category, I was delighted to enter such a prestigious competition. I was thrilled to be shortlisted, and winning first prize is undoubtedly one of the highlights of my 50-year career of trying to bring the wonders of the microscopic world to all.' This year's prize drew submissions from over 100 countries. The Top 25 entries featured over 30 individuals from 18 countries, spanning Bangladesh, Brazil, France, Germany, Greece, India, Italy, Myanmar, Peru, South Africa, Spain, Uganda, the UK, USA and beyond. The winners were selected by an international judging panel comprising leading voices from photography, science, health and journalism. The panel was chaired by Melanie Keen, Director of Wellcome Collection, and included Caroline Hunter, Picture Editor at The Guardian ; Daniella Zalcman, Photographer and Founder of Women Photograph; Benjamin Ryan, Independent Science Journalist; Elizabeth Wathuti, Environmental and Climate Activist; Esmita Charani, Associate Professor at the University of Cape Town; Helen Fisher, Professor of Developmental Psychopathology at King's College London; Noah Green, Science Educator at the Beautiful Biology Initiative; and Mark Lythgoe, Director of the UCL Centre for Advanced Biomedical Imaging. Wellcome Photography Prize Exhibition Curated by Laurie Britton Newell and Ligaya Salazar, the Wellcome Photography Prize exhibition features images that reflect a wide spectrum of health experiences, from everyday routines to global challenges. Using techniques such as portraiture, cyanotypes, drone photography, and light and electron microscopy, the image makers show how health is lived, documented and researched around the world. Many of the works respond to Wellcome's core focus areas, mental health, climate and health, infectious disease and discovery research. Together, they reveal how these issues overlap and take shape in different cultural and geographic contexts. The result is a layered and often unexpected portrait of health today, told through voices and perspectives that are frequently overlooked. Among this year's highlights are Marks of Majesty: Vanessa by Julia Comita and Stephanie Francis, a portrait honouring the life and choices of a person impacted by breast cancer who opted for aesthetic flat closure, challenging assumptions around gender, illness and identity. Beautiful Disaster by Alexandru Radu Popescu shows a lake of toxic mining waste in Romania that continues to expand each year, an image of both striking beauty and environmental damage. Resilience Artist by Pyaephyo Thetpaing captures a craftsman in Myanmar who creates lacquerware using his foot, offering a broader reflection on health, disability and the role of cultural tradition in healing. In the scientific imaging category, Ice and Fire Chronics by Ingrid Augusto, Kildare Rocha de Miranda and Vânia da Silva Vieira shows the structure of the parasite that causes Chagas disease, which affects millions across the Americas. Blooming Barrier by Lucy Holland presents goblet cells inside the gut of a child with Hirschsprung's disease, offering insight into how cell structures influence lifelong digestive health. From Butterflies to Humans by Amaia Alcalde Anton reveals the brain of a butterfly mid-metamorphosis, part of a study into neurogenesis with implications for human brain development. In addition to the Top 25 entries, the exhibition also features Things We Left Unseen , a youth-led photography project developed by Cape Town-based public health organisation Eh!woza. Created in collaboration with young people in the township of Khayelitsha, the project explores health, stigma, and daily life through the eyes of a generation growing up with high HIV and TB burdens, but also with hope and agency. The exhibition is hosted at the Francis Crick Institute, reflecting a shared commitment to making science more visible through culture. Ali Bailey, Director of Communications and Public Engagement at the Francis Crick Institute, said: ' We are delighted to host the top images from the Wellcome Photography Prize, showcasing the power of visual storytelling in health and science. The images explore a number of themes that resonate with Crick research, from the health effects of air pollution to neurogenesis. We hope visitors will be moved by the stories behind these incredible photos and also inspired by how beautiful science can be.' Notes to Editors: Media Contacts Sophie Balfour-Lynn Sutton Sophiebl@ Mary-Kate Findon Wellcome mediaoffice@ Winners' Biographies Sujata Setia (Storytelling Series) Sujata Setia is an Indian-born, UK-based artist who's socially engaged, research-led practice combines photography with traditional artistic interventions to explore subaltern histories, cultural imperialism, and the politics of representation. With a background in journalism and a Master's in International Relations from King's College London, her work draws on academic research and community collaboration to centre marginalised voices, particularly through a feminist lens. Her acclaimed series Changing the Conversation marked a shift away from her earlier portraiture, interrogating the cultural and political construction of beauty. In 2024, she was awarded the Culture King's Grant to develop a lens-based, interdisciplinary project exploring the role of workplace structures for embroidery women artisans in Kashmir. She also recently received the Centre for British Photography Realisation Grant to further expand the scope of A Thousand Cuts , a powerful body of work amplifying the voices of survivors of gender-based abuse. Setia's work has received major international recognition, including the Sony World Photography Award (Creative category, 2024), LensCulture Critics' Choice Award (2024), Prix Pictet nomination (2023), BJP Female in Focus (2022), and Photographer of the Year at the Tokyo International Foto Awards (2021). Her photography has been exhibited widely—from Somerset House in London to Times Square in New York—and featured in leading publications including The Guardian , CNN , BBC , and Forbes . Beyond her visual practice, Setia contributes to education and advocacy through teaching ethical storytelling and photography at EFTI in Madrid, and through collaborations with organisations such as SHEWISE and WERESTART in the UK. Her work consistently seeks to reshape public narratives around identity, power, and care through interdisciplinary, justice-focused art. Mithail Afrige Chowdhury (Striking Solo Photography) Mithail Afrige Chowdhury is a documentary and street photographer based in Dhaka, Bangladesh. Raised in the city of Khulna, his photography is deeply rooted in the lives of ordinary people. 'Since then, I have always tried to understand people's lives—their pain, joy, and the complexities shaped by social, economic, political, and environmental changes.' He began photography in 2015 and chose to document what he knew best: life around him. His work has captured the Rohingya refugee crisis , the effects of climate change on Bangladesh (an ongoing project), major festivals, urban water crises, slum fires, and the Covid-19 pandemic. Mithail has won numerous international photography awards, including the Life Press Photo Award (Ukraine), Xposure International Photography Competition (UAE), Compass Photo Competition by the University of Oxford (UK), and contests in China. His work has been featured in The Guardian , The Daily Sun , The Times of India , Global Photography , and publications from the University of Oxford , ASCE , and Saturday Magazine . Steve Gschmeissner (The Marvels of Medical and Scientific Imaging) Steve Gschmeissner is a UK-based photographer and electron microscopy specialist whose career spans over four decades in scientific imaging. After earning a degree in Zoology, he spent 25 years at the Royal College of Surgeons, eventually leading the electron microscopy services, followed by 15 years leading the EM unit at Cancer Research UK. In 2002, Gschmeissner retired early to dedicate himself to freelance photography, specialising in Scanning Electron Microscopy (SEM). Over the past two decades, he has built an archive of more than 10,000 images, widely published across scientific, medical, and popular media. His work has featured in everything from textbooks and advertising to art, fashion, and music, appearing on album covers for Peter Gabriel, artworks by Damien Hirst, on US Postal Service stamps, and as visual inspiration for an Iris van Herpen's fashion collection. In 2021, he was awarded the Lennart Nilsson Award for his lifelong contribution to microscopy. His images continue to bridge the worlds of science and visual culture, offering new ways of seeing the invisible. Full list of Finalists - Top 25 Entries Striking solo photography A storytelling series The marvels of scientific and medical imaging Exhibition Details Wellcome Photography Prize 2025 exhibition is curated by Laurie Britton Newell and Ligaya Salazar At the Francis Crick Institute, 1 Midland Road, London, NW1 1AT 17 July – 18 October 2025 Open Wednesdays to Saturdays, 10am-4pm (Wednesdays until 8pm) Admission free About Wellcome Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we're taking on three worldwide health challenges: mental health, infectious disease and climate and health. Follow the prize: Instagram: @wellcomephotoprize Wellcome Photography Prize 2025 | Wellcome About the Francis Crick Institute We are delighted that the Crick are hosting this year's Wellcome Photography Prize exhibition. The Francis Crick Institute is a biomedical discovery institute with the mission of understanding the fundamental biology underlying health and disease. Its work helps improve our understanding of why disease develops which promotes discoveries into new ways to prevent, diagnose and treat disease. An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London. The Crick was formed in 2015, and in 2016 it moved into a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe. A photo accompanying this announcement is available at
Yahoo
2 hours ago
- Yahoo
U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott
The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "U.S. Acute External Ventricular Drain Market Size, Share & Trends Analysis Report By Application (Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage), By Patient Type (Pediatric, Adult), And Segment Forecasts, 2025 - 2030" report has been added to U.S. acute external ventricular drain market size was valued at USD 86.5 million in 2024 and is projected to grow at a CAGR of 7.9% from 2025 to 2030 The growth is expected to be driven by the rising prevalence of non-traumatic hydrocephalus, increased demand for minimal or noninvasive neurosurgeries, and the rising adoption of technologically improved devices. With the growing incidence of accidents, sports injuries, and strokes, the demand for external ventricular drain (EVD) procedures is rising steadily. As the aging population expands, the prevalence of conditions like strokes and aneurysms rises, further boosting the need for EVD procedures. For instance, according to the World Bank Group, the total population aged 65 and above in the U.S. was 49.98 million in 2018, increasing to 58.38 million in 2023. In addition, advancements in healthcare infrastructure and the rising number of emergency and trauma centers equipped to handle acute neurological cases contribute to market innovations in EVD systems, such as improved catheter designs, antimicrobial coatings, and integrated monitoring capabilities, enhance patient outcomes and reduce infection risks, making these devices more appealing to healthcare providers. Hospitals and clinics increasingly adopt these advanced EVD systems to improve treatment efficiency and minimize complications. Moreover, the growing emphasis on minimally invasive neurosurgical techniques supports the demand for EVDs, as they offer a less invasive solution for managing CSF drainage than traditional surgical factor fueling market expansion is the rising healthcare expenditure in the U.S., coupled with favorable reimbursement policies for neurological procedures. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 7.5% in 2023, reaching USD 4.9 trillion, which amounts to USD 14,570 per person. Insurance coverage for EVD placements and related treatments ensures broader patient access, encouraging hospitals to invest in these devices. Furthermore, increased physician awareness about the benefits of early and effective CSF management in critical care settings drives higher adoption rates.U.S. Acute External Ventricular Drain Market Report SegmentationApplication Outlook (Revenue, USD Million, 2018 - 2030) Traumatic Brain Injury Subarachnoid hemorrhage Intracerebral hemorrhage Other Non-Traumatic Hydrocephalus conditions Patient Type Outlook (Revenue, USD Million, 2018 - 2030) Pediatric Adult Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $86.5 Million Forecasted Market Value (USD) by 2030 $135.8 Million Compound Annual Growth Rate 7.9% Regions Covered United States U.S. Acute External Ventricular Drain Market Variables, Trends & Scope Market Lineage Outlook Parent market outlook Related/ancillary market outlook Market Dynamics Market driver analysis Market restraint analysis U.S. Acute External Ventricular Drain Market Analysis Tools Industry Analysis - Porter's PESTEL Analysis U.S. Acute External Ventricular Drain Market: Pipeline Analysis Companies Featured Medtronic Integra LifeSciences Corporation Anuncia Medical, Inc. Natus Fuji Systems B Braun/Aesculap Boston Scientific Abbott For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Acute External Ventricular Drain Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
